BioMedBC
Molecular profiling of Bladder Cancer to support personalized medicine
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BioMedBC project word cloud
Explore the words cloud of the BioMedBC project. It provides you a very rough idea of what is the project "BioMedBC" about.
Project "BioMedBC" data sheet
The following table provides information about the project.
| Coordinator |
MOSAIQUES DIAGNOSTICS GMBH
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Project website | https://biomedbc.eu/biomedbc-home |
| Total cost | 159˙460 € |
| EC max contribution | 159˙460 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2016 |
| Funding Scheme | MSCA-IF-EF-SE |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-04-01 to 2019-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MOSAIQUES DIAGNOSTICS GMBH | DE (HANNOVER) | coordinator | 159˙460.00 |
Map
Project objective
BioMedBC Proposal is focused on improving the patient management of Bladder Cancer (BC). BC presents with the highest recurrence rate and the highest associated costs of all cancers. Due to the intrinsic heterogeneity, the investigated drugs in clinical trials, cannot be easily introduced in the clinical practice. Molecular profiles/ biomarkers (BM) with predictive potential are required to enable patient stratification. The BioMedBC proposal aims at the application of systems biology and cross-omics data integration methodologies to achieve: a) the molecular characterization of BC and b) develop signatures to predict the clinical outcome. To achieve these goals, integration of: i) high resolution proteomics datasets (planned to be acquired within BioMedBC), ii) existing datasets that were obtained in previous EU collaborative projects and iii) publicly available transcriptomics data, will be conducted, focusing on the molecular characterization of BC. Emphasis is given on the investigation of disease prognosis. For this purpose, clinical and follow-up data, available from ongoing prospective studies (n=1758), will be utilized for correlation analysis of the molecular profiles/ biomarkers with disease outcome (recurrence, progression and survival). The prognostic value will be confirmed in newly collected samples with emphasis placed on urinary protein/ peptide profiles, as non-invasive urinary markers is of significant added value. The innovation is held on the prognostic BM that can be further used to stratify patients to those that could be benefited by a potential intervention and guide personalized therapy to improve BC patient management. In parallel, BioMedBC aims at expanding upon the current training of the ER, Dr. Maria Frantzi, on transferability of the basic research results to clinically useful products and create strong career prospects for her desired development as an owner of a future SME.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Magdalena Krochmal, Kim E. M. van Kessel, Ellen C. Zwarthoff, Iwona Belczacka, Martin Pejchinovski, Antonia Vlahou, Harald Mischak, Maria Frantzi Urinary peptide panel for prognostic assessment of bladder cancer relapse published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-019-44129-y |
Scientific Reports 9/1 | 2019-09-30 |
| 2018 |
Agnieszka Latosinska, Maria Frantzi, Axel S. Merseburger, Harald Mischak Promise and Implementation of Proteomic Prostate Cancer Biomarkers published pages: 57, ISSN: 2075-4418, DOI: 10.3390/diagnostics8030057 |
Diagnostics 8/3 | 2019-09-30 |
| 2018 |
Agnieszka Latosinska, Maria Frantzi, Antonia Vlahou, Axel S. Merseburger, Harald Mischak Clinical Proteomics for Precision Medicine: The Bladder Cancer Case published pages: 1700074, ISSN: 1862-8346, DOI: 10.1002/prca.201700074 |
PROTEOMICS - Clinical Applications 12/2 | 2019-09-30 |
| 2018 |
Maria Frantzi, Agnieszka Latosinska, Georgia Kontostathi, Harald Mischak Clinical Proteomics: Closing the Gap from Discovery to Implementation published pages: 1700463, ISSN: 1615-9853, DOI: 10.1002/pmic.201700463 |
PROTEOMICS 18/14 | 2019-09-30 |
| 2017 |
Iwona Belczacka, Agnieszka Latosinska, Jochen Metzger, David Marx, Antonia Vlahou, Harald Mischak, Maria Frantzi Proteomics biomarkers for solid tumors: Current status and future prospects published pages: 49-78, ISSN: 0277-7037, DOI: 10.1002/mas.21572 |
Mass Spectrometry Reviews 38/1 | 2019-09-30 |
| 2019 |
Maria Frantzi, Harald Mischak, Agnieszka Latosinska Clinical Proteomics on the Path Toward Implementation: First Promises Delivered published pages: 1800094, ISSN: 1862-8346, DOI: 10.1002/prca.201800094 |
PROTEOMICS – Clinical Applications 13/2 | 2019-09-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMEDBC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BIOMEDBC" are provided by the European Opendata Portal: CORDIS opendata.